Scimago Lab
powered by Scopus
Formerly the IP & Science
business of Thomson Reuters


eISSN: 1643-3750

Get your full text copy in PDF

Long-term survival in primary breast cancer: correlation with estrogen and progesterone receptor assay results and adjuvant tamoxifen therapy

Stanisław J. Chrapusta, Jerzy Giermek, Tadeusz Pieńkowski

Med Sci Monit 2004; 10(10): CR577-586

ID: 11787

Background:The presence of sex steroid receptors in breast cancer tissue is of considerable diagnostic/prognostic value. However, the relative utility of the diverse assays used for receptor detection/quantitation is disputed. We compared the utility of a monoclonal antibody-based semiquantitative immunohistochemical assay of estrogen receptor alpha (irERalpha) and of quantitative single-point radioligand assays of “cytosolic” estrogen (ERc) and progesterone receptors (PRc).Material/Methods: Correlations were studied between the receptor levels in 235 breast cancers in patients treated between 1987 and 1990. Relationships were then analyzed between tumor receptor status, overall survival (OS; end-point: 10 years postmastectomy), age, axillary nodal status, and adjuvant tamoxifen in primary breast cancer patients for whom the respective data were accessible (N ≤121).Results: Univariate analysis showed no correlation between OS and the ERc status, whereas positive irERalpha status was a favorable (p

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree